Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential opportunities for traders before the market opens [1] Group 1: Premarket Gainers - Abpro Corporation (ABP) is up 80% at $2.74 [3] - Ichor Holdings, Ltd. (ICHR) is up 18% at $40.50 [3] - Microbot Medical Inc. (MBOT) is up 17% at $2.16 [3] - Credo Technology Group Holding Ltd (CRDO) is up 16% at $143.65 [3] - Energy Services of America Corporation (ESOA) is up 15% at $11.00 [3] - Biomerica, Inc. (BMRA) is up 10% at $2.40 [3] - PodcastOne, Inc. (PODC) is up 9% at $3.28 [3] - Clear Channel Outdoor Holdings, Inc. (CCO) is up 7% at $2.36 [3] - OFG Bancorp (OFG) is up 6% at $44.39 [3] - Onity Group Inc. (ONIT) is up 6% at $44.30 [3] Group 2: Premarket Losers - Tectonic Therapeutic, Inc. (TECX) is down 37% at $15.49 [4] - Upwork Inc. (UPWK) is down 24% at $14.18 [4] - Everbright Digital Holding Limited (EDHL) is down 12% at $3.11 [4] - Fly-E Group, Inc. (FLYE) is down 12% at $2.51 [4] - Amentum Holdings, Inc. (AMTM) is down 11% at $32.34 [4] - ZoomInfo Technologies Inc. (GTM) is down 10% at $6.54 [4] - REGENXBIO Inc. (RGNX) is down 9% at $9.31 [4] - Momentus Inc. (MNTS) is down 8% at $5.90 [4] - The Goodyear Tire & Rubber Company (GT) is down 7% at $9.70 [4] - GRI Bio, Inc. (GRI) is down 6% at $2.30 [4]

Market Overview - U.S. stocks traded lower, with the Nasdaq Composite falling over 2% on Wednesday, Dow down 0.67% to 40,099.73, and S&P 500 down 1.27% to 5,327.95 [1] - Energy shares surged by 1.4%, while information technology shares fell by 3% [1] Company Performance - Abbott Laboratories reported first-quarter sales of $10.36 billion, a 7.2% year-over-year increase, and adjusted EPS of $1.09, beating consensus of $1.07 [2] - Abbott expects second quarter 2025 adjusted EPS of $1.23-$1.27, slightly above consensus of $1.25 [2] Commodity Prices - Oil prices increased by 16% to $62.33, gold rose by 2.6% to $3,323.10, silver up 1.7% to $32.860, and copper increased by 0.1% to $4.6310 [5] Stock Movements - Treasure Global Inc. shares surged 70% to $3.54 after securing an exclusive partnership with Mezzofy [9] - iCAD, Inc. shares rose 67% to $3.22 following an acquisition announcement by RadNet for approximately $103 million [9] - SUNation Energy Inc. shares dropped 40% to $0.0249 due to a 1-for-200 reverse stock split [9] - Biomerica, Inc. shares fell 30% to $0.4006 after announcing a 1-for-8 reverse stock split [9]

Core Viewpoint - Biomerica, Inc. will implement a 1-for-8 reverse stock split to increase the bid price of its common stock and regain compliance with Nasdaq's minimum bid price requirement [2][3]. Group 1: Reverse Stock Split Details - The reverse stock split will take effect at 12:01 a.m. Eastern time on April 21, 2025, with trading on a split-adjusted basis starting the same day [1]. - The number of shares outstanding will decrease from approximately 20,366,095 shares to about 2,545,762 shares, while the number of authorized shares will remain unchanged [3]. - Stockholders will automatically have fractional shares rounded up to the next whole share, and adjustments will be made to equity awards and option exercise prices accordingly [3][4]. Group 2: Compliance and Authorization - The reverse stock split was authorized by Biomerica's stockholders during the 2024 Annual Meeting held on December 13, 2024, with the final ratio determined by the Board of Directors [2]. - The company aims to enhance its stock price to meet Nasdaq's listing requirements, which is critical for its continued presence on the exchange [2]. Group 3: Company Overview - Biomerica, Inc. is a global biomedical technology company focused on developing advanced diagnostic and therapeutic products for medical conditions, particularly gastrointestinal and inflammatory diseases [6]. - The company markets products designed to improve health outcomes while reducing healthcare costs, with a strong emphasis on point-of-care testing [6].

Core Insights - BioLife Solutions, Inc. has appointed Cathy Coste to its board of directors, increasing the total board membership to seven [1] - Ms. Coste will serve as chair of the audit committee, succeeding Joydeep Goswami, who will remain a director and member of the audit committee [1] Company Overview - BioLife Solutions is a leading developer and supplier of bioproduction tools and services specifically for the cell and gene therapy (CGT) market [4] - The company focuses on maintaining the health and function of biologic materials during their collection, development, storage, and distribution [4] Leadership and Expertise - Cathy Coste brings over four decades of experience as a senior executive, with a strong background in audits, risk and controls, and compliance [2] - She has worked with more than two dozen life sciences companies during her tenure at Deloitte and has extensive experience in governance initiatives and strategic planning [2][3] - Ms. Coste has served as a director and audit committee chair for multiple companies, including Biomerica, Inc., Minerva Surgical, Inc., and Renalytix plc [3] Future Outlook - Ms. Coste expressed optimism about BioLife's position for revenue growth and sustained profitability following its transition to a pure-play enabler of cell and gene therapies [2]